Clinical trial · Observational
Breast Cancer After Ovarian Cancer During and/or After Therapy: Genomic Evaluation
Molecular Landscape Involved in the Onset of Breast Cancer in Patients With Germline BRCA-1/2 Mutations, During or After Therapy With Platinum-based Agents and/or PARP-inhibitors for Ovarian Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will investigate, in patients with germline BRCA-1/2 mutations and breast cancer, arising during and / or after treatment with platinum-based chemotherapy and / or with PARP-inhibitors for ovarian cancer, the presence of molecular alterations potentially involved in the mechanisms of resistance to antineoplastic treatment on breast and ovarian tumor tissue.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| BRCA-Associated Breast Carcinoma | BRCA Hereditary Breast Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Next-generation sequencing (NGS) assay TruSight Oncology 500 (TSO 500). | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with germline BRCA1/2 patitents
- description
- Women with germline BRCA-1/2 mutations, previously treated or undergoing treatment with platinum-based chemotherapy and/or PARP inhibitors for ovarian cancer, who have developed breast cancer, subjected to genomic profiling of breast and ovarian tumor samples.
- interventionNames
- Genetic: Next-generation sequencing (NGS) assay TruSight Oncology 500 (TSO 500).
Primary outcomes (1)
- measure
- Breast somatic mutations
- timeFrame
- 15 months
- description
- To describe the presence of somatic mutations on breast tumor tissue, in patients with breast cancer arising during or after treatment with platinum-based chemotherapy or PARP-inhibitors for ovarian cancer.
Secondary outcomes (1)
- measure
- Ovarian somatic mutations
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Written informed consent. * Age older than 18 years. * Germline BRCA1/2 mutation. * Histologically confirmed ovarian cancer treated with platinum-based chemotherapy and/or PARP inhibitors. * Histologically confirmed breast cancer occurred during or after therapy with platinum-based agents and/or PARP-inhibitors for ovarian cancer. * Availability of FFPE breast and ovarian tumor samples. Exclusion Criteria: * Other malignancies in the last 2 years. * Prior chemotherapy or radiation therapy for other malignancies.
References
Publications (0)
Data not yet available